Biological diversity & Nagoya protocol
Novozymes' position statement on biodiversity Including confirmation of compliance with the Convention on Biological Diversity and the Nagoya protocol
The United Nations Convention on Biodiversity is an international legal instrument for the conservation and sustainable use of biological diversity. The Convention on Biological Diversity (CBD) was inspired by the world community's growing commitment to sustainable development.
The CBD has been in force since December 1993. With the entry into force of the Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization in Oct. 2014, the CBD was complemented with more specific guidance on Access and Benefit Sharing (ABS).
Novozymes supports the UN Convention on Biological Diversity in terms of "the fair and equitable sharing of the benefits arising out of the utilization of genetic resources". Novozymes endorses the globally recognized principles on the utilization of genetic resources according to the CBD.
Novozymes acknowledges and respects the principles of both the CBD and the Nagoya protocol and the company has internal procedures to ensure that it lives up to its commitments.
Novozymes promotes fair and equitable sharing of the benefits arising from the utilization of genetic resources and promotes appropriate access to such resources, as internationally agreed. We regularly assess outcomes of CBD meetings with a view to undertake a broader strategic discussion on its management and reporting of biodiversity issues.